Serum uric acid levels and risk of cardiovascular disease in type 2 diabetes: results from a cross-sectional study and Mendelian randomization analysis.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 01 07 2023
accepted: 23 10 2023
medline: 1 12 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Serum uric acid (SUA) levels have been previously linked to a higher risk of cardiovascular disease (CVD) in individuals with type 2 diabetes (T2D) according to various observational studies. However, whether this association is causally linked or simply influenced by confounding factors is unclear. Therefore, this study utilized Mendelian randomization (MR) analysis to explore the causality between SUA levels and the risk of CVD in individuals with T2D. Our study cohort consisted of 5723 participants who were diagnosed with T2D in the National Health and Nutrition Examination Survey (NHANES) from 1999-2018. The study assessed the association between SUA levels and the risk of CVD using a multivariable logistic regression model. To further examine causality between SUA levels and CVD, a two-sample MR study was conducted utilizing genetic data from genome-wide association studies (GWAS) involving over 140,000 individuals. The main MR analysis employed the inverse-variance-weighted (IVW) method. Additionally, several sensitivity analyses were performed to evaluate the robustness and pleiotropy of the results. In the cross-sectional study, after multivariable adjustment, participants with SUA levels >6.7 mg/dL exhibited odds ratios (ORs) of 1.51 (95% CI: 1.01-2.26, p=0.049) for heart failure, 1.02 (95% CI: 0.69-1.50, p=0.937) for coronary heart disease, 1.36 (95% CI: 0.78-2.38, p=0.285) for angina, and 1.22 (95% CI: 0.80-1.85, p=0.355) for myocardial infarction when compared to participants with SUA levels ≤ 4.6 mg/dL. However, in the IVW analysis, no causality between SUA levels and the risk of heart failure was observed (OR = 1.03, 95% CI: 0.97-1.09, p = 0.293). The secondary analysis yielded similar results (OR = 1.05, 95% CI: 0.96-1.14, p = 0.299). The sensitivity analyses further supported our primary findings. Based on the MR study, we did not find supporting evidence for a causal association between SUA levels and the risk of heart failure.

Identifiants

pubmed: 38027101
doi: 10.3389/fendo.2023.1251451
pmc: PMC10664243
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1251451

Informations de copyright

Copyright © 2023 He, Feng, Zhang, Wu, Zhou, He, Zheng and Yang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Circulation. 2006 Dec 5;114(23):2508-16
pubmed: 17130343
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Stat Methods Med Res. 2017 Oct;26(5):2333-2355
pubmed: 26282889
Circulation. 2015 May 19;131(20):1763-71
pubmed: 25986447
Ann Intern Med. 1999 Jul 6;131(1):7-13
pubmed: 10391820
BMJ. 2021 Jan 13;372:m4573
pubmed: 33441402
Lancet Diabetes Endocrinol. 2015 May;3(5):356-66
pubmed: 25791290
Cardiovasc Diabetol. 2020 Nov 10;19(1):191
pubmed: 33172464
J Am Coll Cardiol. 2008 Jun 17;51(24):2301-9
pubmed: 18549913
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Lancet. 2007 Aug 18;370(9587):591-603
pubmed: 17707755
Lancet. 2021 Aug 28;398(10302):786-802
pubmed: 34175022
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Lancet Diabetes Endocrinol. 2013 Oct;1(2):106-14
pubmed: 24622316
Int J Epidemiol. 2003 Feb;32(1):1-22
pubmed: 12689998
JAMA. 2011 Jun 22;305(24):2532-9
pubmed: 21693741
Circulation. 2002 Jul 9;106(2):221-6
pubmed: 12105162
Ann Intern Med. 2020 Feb 4;172(3):186-194
pubmed: 31931526
Diabetologia. 2018 Jan;61(1):21-28
pubmed: 28776083
J Clin Invest. 2010 Jun;120(6):1791-9
pubmed: 20516647
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
BMJ. 2011 Jul 26;343:d4169
pubmed: 21791495
Hepatology. 2014 Oct;60(4):1139-49
pubmed: 24500979
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
Med Chir Trans. 1848;31:83-97
pubmed: 20895908
Nat Commun. 2020 Jan 9;11(1):163
pubmed: 31919418
Cardiovasc Diabetol. 2021 Jul 27;20(1):154
pubmed: 34315481
JAMA Netw Open. 2022 Jan 4;5(1):e2146124
pubmed: 35099545
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977
Nat Rev Endocrinol. 2022 Sep;18(9):525-539
pubmed: 35668219
Int J Mol Sci. 2021 Aug 26;22(17):
pubmed: 34502127
J Am Soc Nephrol. 2016 Nov;27(11):3253-3265
pubmed: 27486138
J Cardiol. 2021 Jul;78(1):51-57
pubmed: 33388217
BMJ. 2017 Jun 7;357:j2376
pubmed: 28592419
Nat Genet. 2013 Feb;45(2):145-54
pubmed: 23263486
Metabolism. 2021 Oct;123:154838
pubmed: 34333002
Diabetes Care. 2023 Feb 1;46(2):425-433
pubmed: 36490263
Atherosclerosis. 2020 Mar;296:49-58
pubmed: 32032905

Auteurs

Ying He (Y)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Jincheng Feng (J)

Department of Liver Transplantation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Bo Zhang (B)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Qiong Wu (Q)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Yongjie Zhou (Y)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Diao He (D)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Daofeng Zheng (D)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Jiayin Yang (J)

Key Laboratory of Transplant Engineering and Immunology, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of General Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH